Compare BHAT & BRNS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BHAT | BRNS |
|---|---|---|
| Founded | 2010 | 2016 |
| Country | China | United Kingdom |
| Employees | N/A | N/A |
| Industry | Recreational Games/Products/Toys | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 27.7M | 55.9M |
| IPO Year | 2019 | 2021 |
| Metric | BHAT | BRNS |
|---|---|---|
| Price | $0.57 | $0.65 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $4.00 |
| AVG Volume (30 Days) | ★ 730.0K | 36.2K |
| Earning Date | 05-12-2026 | 03-19-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $18,972,415.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 1766.46 |
| 52 Week Low | $0.51 | $0.56 |
| 52 Week High | $9.10 | $2.92 |
| Indicator | BHAT | BRNS |
|---|---|---|
| Relative Strength Index (RSI) | 24.17 | 32.40 |
| Support Level | $0.51 | $0.56 |
| Resistance Level | $0.75 | $0.75 |
| Average True Range (ATR) | 0.11 | 0.04 |
| MACD | -0.03 | -0.01 |
| Stochastic Oscillator | 4.73 | 34.53 |
Blue Hat Interactive Entertainment Technology is focused on commodity trading, including chemicals, jewelry, and precious metals such as gold. It operates a gold and diamond trading and supply chain business. Its business model encompasses physical gold trading, diamond trading, gold derivatives trading, and the development of AI-enabled trading platforms. Its segments include Diamond trading, Commodity trading, Information service, Interactive toys - animation series, and Interactive toys - game series. It derives revenue from Diamond trading. The majority of its revenues are generated in PRC.
Barinthus Biotherapeutics PLC is a clinical-stage biopharmaceutical company developing novel T-cell immunotherapeutics that guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. The company operates as one segment, the research and development of immunotherapies and vaccines.